Respiratory syncytial virus (RSV) vaccination is recommended in pregnancy. Limited data exist regarding antibody (Ab) durability to inform revaccination timing. We conducted prospective cohort studies among pregnant and older adults after first RSV vaccination in 2023-2024. Longitudinal samples from 50 pregnant (36 vaccinated) and 16 vaccinated older adults were collected until 12-15 months after vaccination and tested for RSV binding and neutralizing Ab. Mean Ab levels 12-15 months after vaccination were similar between vaccinated maternal and older adult participants (P = .73), suggesting Ab durability up to 1 year after maternal RSV vaccination. RSV binding and neutralizing Ab titers were strongly correlated (R = .73).
Kachikis et al. (Thu,) studied this question.